REGN Regeneron Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Jul 30, 2026REGN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
REGN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Regeneron Pharmaceuticals, Inc. - Common Stock Company overview from Wikipedia
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Company history
The company was founded by CEO Leonard Schleifer and scientist George Yancopoulos in 1988.
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
On March 26, 2012, Bloomberg announced that Sanofi and Regeneron were in development of a new drug that would help reduce cholesterol up to 72% more than its competitors. The new drug would target the PCSK9 gene.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof-of-concept data, and $650 million from the development of REGN2810. REGN2810 was later named cemiplimab. In 2019, Regeneron Pharmaceuticals was announced the 7th best publicly listed company of the 2010s, with a total return of 1,457%. Regeneron Pharmaceuticals was home to the two highest-paid pharmaceutical executives as of 2020.
In October 2017, Regeneron made a deal with the Biomedical Advanced Research and Development Authority (BARDA) that the U.S. government would fund 80% of the costs for Regeneron to develop and manufacture antibody-based medications, which subsequently, in 2020, included their COVID-19 treatments, and Regeneron would retain the right to set prices and control production. This deal was criticized in The New York Times. Such deals are not unusual for routine drug development in the American pharmaceutical market.
In 2019, the company was added to the Dow Jones Sustainability World Index.
In May 2020, Regeneron announced it would repurchase approx. 19.2 million of its shares for around $5 billion, held directly by Sanofi. Prior to the transaction, Sanofi held 23.2 million Regeneron shares.
In August 2023, Regeneron announced it would acquire Decibel Therapeutics.
In May 2025, the company was awarded $135.6 million in compensatory damages and $271.2 million in punitive damages in the United States District Court for the District of Delaware in a victorious antitrust case filed against Amgen. Regeneron alleged Amgen employed anticompetitive practices to exclude Praluent from the market and elevate Amgen's rival Repatha.
Experimental treatment for COVID-19
On February 4, 2020, the U.S. Department of Health and Human Services, which already worked with Regeneron, announced that Regeneron would pursue monoclonal antibodies to fight COVID-19.
In July 2020, under Operation Warp Speed, Regeneron was awarded a $450 million government contract to manufacture and supply its experimental treatment REGN-COV2, an artificial "antibody cocktail" which was then undergoing clinical trials for its potential both to treat people with COVID-19 and to prevent SARS-CoV-2 coronavirus infection. The $450 million came from the Biomedical Advanced Research and Development Authority (BARDA), the DoD Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, and Army Contracting Command. Regeneron expected to produce 70,000–300,000 treatment doses or 420,000–1,300,000 prevention doses. "By funding this manufacturing effort, the federal government will own the doses expected to result from the demonstration project," the government said in its July 7 news release. Regeneron similarly said in its own news release that same day that "the government has committed to making doses from these lots available to the American people at no cost and would be responsible for their distribution," noting that this depended on the government granting emergency use authorization or product approval. California based laboratory, FOMAT, is part of the clinical investigation through their doctors Augusto and Nicholas Focil.
In October 2020 when U.S. President Donald Trump was infected with COVID-19 and taken to Walter Reed National Military Medical Center in Bethesda, Maryland, he was administered REGN-COV2. His doctors obtained it from Regeneron via a compassionate use request (as clinical trials had not yet been completed and the drug had not yet been approved by the US Food and Drug Administration (FDA)). On October 7, Trump posted a five-minute video to Twitter reasserting that this drug should be "free." That same day, Regeneron filed with the FDA for emergency use authorization. In the filing, it specified that it currently had 50,000 doses and that it expected to reach a total of 300,000 doses "within the next few months." The FDA granted approval for emergency use authorization in November 2020.
Marketed products
Arcalyst (rilonacept) is used for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
Eylea (aflibercept injection) was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to treat a common cause of blindness in the elderly. Eylea is reported to cost $11,000 per year for each eye treated.
Zaltrap (aflibercept injection) is used for metastatic colorectal cancer approved by the FDA in August 2012.
Praluent (alirocumab) is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by the FDA in July 2015, It is reported to cost $4,500 to $8,000 per year.
Dupixent (dupilumab injection) is for the treatment of adolescent and adult patients' atopic dermatitis. It was approved by the FDA in March 2017 and is reported to cost $37,000 per year.
Kevzara (sarilumab injection) is an interleukin-6 (IL-6) receptor antagonist for treatment of adults with rheumatoid arthritis approved by the FDA in May 2017. Trials commenced in March 2020 to evaluate the effectiveness of Kevzara in the treatment of COVID-19.
Libtayo (cemiplimab injection) is a monoclonal antibody targeting the PD-1 pathway as a checkpoint inhibitor, for the treatment of people with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Libtayo was approved by the FDA in September 2018.
Inmazeb (atoltivimab/maftivimab/odesivimab) is a drug made of three antibodies, developed to treat deadly Ebola virus. In October 2020, the U.S. Food and Drug Administration (FDA) approved it with an indication for the treatment of infection caused by Zaire ebolavirus.
Veopoz (pozelimab-bbfg) is a fully human monoclonal antibody targeting complement factor C5, a protein involved in complement system activation. In August 2023, it was approved by the FDA for children and adults with CHAPLE disease or CD55-deficient protein-losing enteropathy.
Technology platforms
Trap Fusion Proteins: Regeneron's Trap technology creates high-affinity product candidates for signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two fully human receptor components and a fully human immunoglobulin-G constant region.
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.
The Regeneron Genetics Center is a distinct subsidiary of Regeneron, focused on sequencing human exomes. To date, the Regeneron Genetics Center has sequenced over 3,000,000 exomes.
Financial performance
Key people
The founders Leonard Schleifer and George Yancopoulos are reported to hold $1.3 billion and $900 million in company stock, respectively. Both are from Queens, New York. Schleifer was formerly a professor of medicine at Weill Cornell Medical School. Yancopoulos was a post-doctoral fellow, and MD/PhD student at Columbia University. Yancopoulos was involved in each drug's development.
In 2026, the Wall Street Journal noted that George Yancopoulos has 1000 patents, and is building Regeneron through internal science and discovery, not acquisitions. .
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | REGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 18.25Y avg ≈18.0 | ≈18.0 | 28.9 | Undervalued | |
| P/S (TTM) | 6.55Y avg ≈7.7 | ≈7.7 | 8.4 | Undervalued | |
| P/B (MRQ) | 3.25Y avg ≈3.8 | ≈3.8 | 13.3 | Undervalued | |
| EV / EBITDA (TTM) | 21.85Y avg ≈21.5 | ≈21.5 | · | · | |
| Price / FCF (TTM) | 27.05Y avg ≈26.0 | ≈26.0 | · | · | |
| Price / Cash Flow (TTM) | 21.75Y avg ≈21.9 | ≈21.9 | 21.3 | Fair value | |
| EV / Revenue (TTM) | 6.15Y avg ≈7.2 | ≈7.2 | · | · | |
| EV / FCF (TTM) | 25.45Y avg ≈24.2 | ≈24.2 | · | · | |
| Price / Tangible Book (MRQ) | 3.35Y avg ≈4.0 | ≈4.0 | · | · | |
| PEG Ratio | ≈2.9 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | REGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 24.7%5Y avg ≈35.7% | ≈35.7% | 8.8% | Top tier | |
| EBITDA Margin (TTM) | 28.1%5Y avg ≈38.7% | ≈38.7% | 8.2% | Top tier | |
| Pretax Margin (TTM) | 33.3%5Y avg ≈40.0% | ≈40.0% | 4.8% | Top tier | |
| Net Profit Margin (TTM) | 27.9%5Y avg ≈35.7% | ≈35.7% | 3.6% | Top tier | |
| ROA (TTM) | 10.8%5Y avg ≈18.1% | ≈18.1% | 6.8% | Top tier | |
| ROE (TTM) | 14.0%5Y avg ≈22.0% | ≈22.0% | 14.7% | In line | |
| ROIC | 9.3%5Y avg ≈17.8% | ≈17.8% | 10.8% | In line |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | REGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.15Y avg ≈0.1 | ≈0.1 | 0.1 | Low debt | |
| Current Ratio (MRQ) | 3.35Y avg ≈4.6 | ≈4.6 | 3.0 | Strong liquidity | |
| Quick Ratio (MRQ) | 2.65Y avg ≈3.8 | ≈3.8 | 0.9 | Strong liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.15Y avg ≈0.1 | ≈0.1 | 0.7 | Low debt |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | REGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 0.99%5Y avg ≈16.4% | ≈16.4% | · | · | |
| Revenue CAGR 3Y | 5.6%5Y avg ≈5.7% | ≈5.7% | · | · | |
| Revenue CAGR 5Y | 11.0% | · | · | · | |
| EPS YoY | 8.2%5Y avg ≈19.7% | ≈19.7% | · | · | |
| Net Income YoY | 2.1%5Y avg ≈17.7% | ≈17.7% | · | · | |
| EPS CAGR 3Y | 2.8%5Y avg ≈-3.9% | ≈-3.9% | · | · | |
| EPS CAGR 5Y | 6.3% | · | · | · | |
| Net Income CAGR 3Y | 1.3%5Y avg ≈-4.3% | ≈-4.3% | · | · | |
| Net Income CAGR 5Y | 5.1% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | REGN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.45Y avg ≈0.5 | ≈0.5 | 0.4 | Weak | |
| Receivables Turnover | 2.45Y avg ≈2.5 | ≈2.5 | 6.3 | Weak | |
| Revenue / Employee | ≈$930.8K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Aug 18, 2026 | $0.94 | USD | ≈0.46% |
| May 20, 2026 | $0.94 | USD | ≈0.56% |
| Feb 20, 2026 | $0.94 | USD | ≈0.46% |
| Nov 20, 2025 | $0.88 | USD | ≈0.48% |
| Aug 18, 2025 | $0.88 | USD | ≈0.45% |
| May 20, 2025 | $0.88 | USD | ≈0.29% |
| Feb 20, 2025 | $0.88 | USD | ≈0.13% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Jul 30, 2026 | $14.29 | $10.47 | 36.5% |
| March 31, 2026 | $9.47 | $9.12 | 3.9% | |
| Dec. 31, 2025 | $11.44 | $10.83 | 5.7% | |
| Sept. 30, 2025 | $11.83 | $9.78 | 21.0% | |
| June 30, 2025 | $12.89 | $8.61 | 49.8% | |
| March 31, 2025 | $8.22 | $9.00 | -8.7% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Cost of Revenue | · | · | · | · | · | · | $403M | $238M | $203M | $195M | $242M | $129M | |
| R&D Expense | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | |
| SG&A Expense | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $839M | $519M | |
| Operating Expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B | $2.85B | $2.00B | |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $824M | |
| Interest Expense | · | · | $73M | $59M | $57M | $57M | $30M | $28M | $25M | $7M | $14M | $37M | |
| Other Non-op | $1.70B | $844M | $225M | $179M | $436M | $291M | $250M | $47M | $24M | $6M | $-13M | $-25M | |
| Pretax Income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B | $1.23B | $761M | |
| Income Tax | $726M | $367M | $246M | $520M | $1.25B | $297M | $313M | $109M | $880M | $434M | $589M | $423M | |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | |
| Shares (Basic) | 104,600,000 | 107,900,000 | 106,700,000 | 107,100,000 | 105,700,000 | 107,600,000 | 109,200,000 | 107,900,000 | 106,300,000 | 104,700,000 | 103,061,000 | 100,612,000 | |
| Shares (Diluted) | 108,600,000 | 115,100,000 | 113,700,000 | 113,500,000 | 112,200,000 | 115,100,000 | 114,600,000 | 114,800,000 | 115,900,000 | 116,300,000 | 115,230,000 | 113,413,000 | |
| EBITDA | $4.12B | $4.47B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $891M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $813M | $535M | $809M | $649M | |
| Short-term Investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B | $1.60B | $1.34B | $597M | $503M | $236M | $252M | |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B | $1.54B | $1.34B | $1.15B | $739M | |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B | $726M | $399M | $239M | $129M | |
| Prepaid Expense | $475M | $349M | $387M | $411M | $332M | $161M | $274M | $243M | $225M | $131M | $164M | $79M | |
| Current Assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B | $2.92B | $2.08B | |
| PP&E (Net) | · | · | · | · | $3.48B | $3.22B | $2.89B | $2.58B | $2.36B | $2.08B | $1.59B | $974M | |
| PP&E (Gross) | · | · | · | · | · | · | $3.81B | $3.30B | $2.92B | $2.51B | $1.93B | $1.23B | |
| Accum. Depreciation | · | · | · | · | · | · | $922M | $729M | $566M | $426M | $331M | $254M | |
| Intangibles | $1.26B | $1.15B | $1.04B | $916M | $7M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $1.82B | $1.14B | $444M | $336M | $216M | $168M | $145M | $127M | $78M | $20M | $6M | $3M | |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Accounts Payable | $939M | $790M | $607M | $589M | $564M | $476M | $418M | $218M | $178M | $879M | $644M | $483M | |
| Short-term Debt | · | · | · | · | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B | $1.14B | $1.24B | $811M | $655M | |
| Capital Leases | $229M | $204M | $69M | $56M | · | · | · | $708M | · | · | · | · | |
| Other Non-current Liabilities | $2.02B | $1.57B | $854M | $638M | $680M | $687M | $318M | $362M | $152M | $100M | $116M | $40M | |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B | $1.95B | $1.29B | |
| Total Debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | · | · | · | · | · | · | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $108.0K | $106.0K | $102.0K | |
| Paid-in Capital | $13.99B | $12.86B | $11.35B | $9.95B | $8.09B | $6.72B | $4.43B | $3.91B | $3.51B | $3.03B | $3.10B | $2.45B | |
| Retained Earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B | $2.95B | $1.75B | $853M | $217M | |
| Treasury Stock | $18.61B | $15.17B | $12.56B | $10.35B | $8.26B | $6.61B | $740M | $396M | $316M | $316M | $306M | $170M | |
| AOCI | $78M | $-8M | $-81M | $-239M | $-26M | $29M | $21M | $-12M | $600.0K | $-13M | $9M | $52M | |
| Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B | $3.65B | $2.55B | |
| Liabilities + Equity | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Shares Outstanding | 137,600,000 | 136,000,000 | 133,100,000 | 130,400,000 | 126,200,000 | 121,500,000 | 113,300,000 | · | · | · | · | · |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $544M | $483M | $421M | $341M | $286M | $236M | $210M | $148M | $146M | $105M | $75M | $53M | |
| Stock-based Comp | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M | $459M | $322M | |
| Deferred Tax | $-785M | $-757M | $-838M | $-746M | $-147M | $76M | $-131M | $-140M | $319M | $-360M | $-130M | $-46M | |
| Amort. of Intangibles | $179M | $129M | $92M | $38M | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-278M | $-700M | $172M | $356M | $-1.73B | $-1.64B | $-230M | $-685M | $-863M | $273M | $291M | $86M | |
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B | $1.33B | $752M | |
| CapEx | $898M | $756M | $719M | $590M | $552M | $615M | $430M | $383M | $273M | $512M | $678M | $333M | |
| Investing Cash Flow | $-629M | $-2.47B | $-3.19B | $-3.78B | $-5.38B | $-71M | $-2.03B | $-1.46B | $-1.01B | $-1.05B | $-908M | $-421M | |
| Debt Issued | · | · | · | $0 | $0 | $1.98B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | · | · | · | $0 | $0 | $1.98B | · | · | · | · | · | · | |
| Stock Issued | $636M | $1.47B | $1.15B | $1.52B | $1.67B | $2.58B | $212M | $114M | $240M | $127M | $206M | $126M | |
| Stock Repurchased | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $276M | $4M | $0 | $0 | · | · | |
| Net Stock Activity | $-2.80B | $-1.14B | $-1.09B | $-563M | $27M | $-3.27B | $-64M | $110M | $240M | $127M | $206M | $126M | |
| Dividends Paid | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-3.72B | $-2.20B | $-1.79B | $-1.01B | $-1.01B | $-1.97B | $-252M | $-77M | $-24M | $-700M | $-263M | $-219M | |
| Net Change in Cash | $635M | $-249M | $-382M | $221M | $691M | $577M | $150M | $655M | $278M | $-261M | $160M | $113M | |
| Taxes Paid | $1.25B | $743M | $870M | $1.50B | $1.22B | $188M | $342M | $206M | $755M | $481M | $276M | $60M | |
| Free Cash Flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $961M | $653M | $410M | |
| Levered FCF | · | · | $3.81B | $4.37B | $6.48B | $1.95B | $1.97B | $1.79B | · | · | $645M | $393M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | |
| Net Margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | |
| Pretax Margin | 36.5% | 33.7% | 32.0% | 39.9% | 58.0% | 44.8% | 30.9% | 38.0% | 35.4% | 27.4% | 29.8% | 27.5% | |
| EBITDA Margin | 28.7% | 31.5% | 34.1% | 41.7% | 57.5% | 44.9% | 30.8% | 40.0% | 37.9% | 29.5% | 32.3% | 31.6% | |
| ROA | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% | 13.5% | 10.2% | |
| ROE | 14.7% | 15.0% | 15.5% | 19.7% | 44.8% | 33.2% | 19.6% | 29.4% | 22.6% | 22.1% | 20.5% | 15.4% | |
| ROIC | 9.3% | 11.8% | 13.6% | 17.2% | 37.3% | 25.4% | 17.4% | 27.7% | 19.5% | 20.1% | 17.8% | 14.8% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 | 3.6 | 3.7 | 4.5 | 3.8 | 2.6 | 3.6 | 3.3 | |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 | 2.5 | 2.5 | 3.1 | 2.6 | 1.9 | 2.7 | 2.5 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | 55.4 | 79.8 | 156.1 | 62.9 | 73.2 | 89.9 | · | · | 87.9 | 22.4 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.5 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.8 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 0.4 | 0.6 | 1.3 | 1.3 | |
| Receivables Turnover | 2.4 | 2.4 | 2.4 | 2.1 | 3.2 | 3.3 | 4.1 | 4.1 | 4.1 | 3.9 | 4.3 | 3.7 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $227.16 | $215.84 | $195.14 | $173.80 | · | · | · | · | · | · | · | · | |
| Revenue / Share | $132.07 | $123.39 | $115.37 | $107.25 | $143.24 | $73.82 | $68.62 | $58.46 | $50.64 | $41.77 | $35.61 | $24.86 | |
| Cash Flow / Share | $45.85 | $38.41 | $40.40 | $44.18 | $63.11 | $22.75 | $21.20 | $19.12 | $11.27 | $12.66 | $11.55 | $6.55 | |
| Cash / Share | $22.66 | $18.30 | $20.51 | $23.82 | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.99% | 8.3% | 7.8% | -24.3% | 89.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.6% | -4.0% | 15.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 8.2% | 10.3% | -9.0% | -46.9% | 135.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 2.8% | -18.9% | 4.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2.1% | 11.6% | -8.9% | -46.3% | 129.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.3% | -18.2% | 4.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 5.1% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Net Income TTM | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| Market Cap | $106.21B | $96.88B | $116.90B | $94.08B | · | · | · | · | · | · | · | · | |
| Enterprise Value | $99.59B | $89.85B | $108.04B | $88.32B | · | · | · | · | · | · | · | · | |
| P/E | 18.6 | 18.6 | 25.3 | 18.9 | 8.8 | 15.8 | 20.3 | 17.5 | 36.4 | 47.7 | 98.3 | 137.7 | |
| P/S | 7.4 | 6.8 | 8.9 | 7.7 | · | · | · | · | · | · | · | · | |
| P/B | 3.4 | 3.3 | 4.5 | 4.2 | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.5 | 3.4 | 4.7 | 4.3 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 21.3 | 21.9 | 25.4 | 18.8 | · | · | · | · | · | · | · | · | |
| P / FCF | 26.0 | 26.4 | 30.2 | 21.3 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | 24.2 | 20.1 | 24.2 | 17.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | 24.4 | 24.5 | 27.9 | 20.0 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 6.3 | 8.2 | 7.3 | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.35% | 0.00% | 0.00% | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% | 1.0% | 0.73% | |
| Payout Ratio | 8.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Annual Payout | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B | $3.36B | $3.16B | $3.16B | $3.41B | $2.94B | |
| R&D Expense | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B | $1.27B | $1.20B | $1.25B | $1.18B | $1.08B | $1.09B | $1.10B | $1.04B | $911M | |
| SG&A Expense | $662M | $648M | $775M | $658M | $634M | $633M | $792M | $714M | $759M | $689M | $738M | $640M | $652M | $601M | $660M | $529M | |
| Operating Expenses | $3.00B | $2.96B | $3.00B | $2.73B | $2.60B | $2.44B | $2.80B | $2.54B | $2.48B | $2.39B | $2.46B | $2.25B | $2.14B | $2.22B | $2.27B | $1.71B | |
| Operating Income | $1.29B | $643M | $880M | $1.03B | $1.08B | $592M | $990M | $1.18B | $1.07B | $751M | $973M | $1.11B | $1.02B | $947M | $1.15B | $1.22B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $16M | · | $18M | $19M | $18M | · | $15M | |
| Other Non-op | $245M | $201M | $176M | $756M | $443M | $322M | $-22M | $327M | $573M | $-35M | $193M | $18M | $85M | $-71M | $195M | $301M | |
| Pretax Income | $1.53B | $831M | $1.04B | $1.76B | $1.52B | $905M | $958M | $1.49B | $1.63B | $701M | $1.15B | $1.11B | $1.08B | $858M | $1.32B | $1.51B | |
| Income Tax | $231M | $104M | $199M | $303M | $127M | $96M | $40M | $152M | $196M | $-21M | $-12M | $103M | $114M | $40M | $128M | $194M | |
| Net Income | $1.30B | $727M | $845M | $1.46B | $1.39B | $809M | $918M | $1.34B | $1.43B | $722M | $1.16B | $1.01B | $968M | $818M | $1.20B | $1.32B | |
| EPS (Basic) | $12.62 | $6.99 | $8.16 | $14.09 | $13.24 | $7.58 | $8.55 | $12.40 | $13.25 | $6.70 | $10.88 | $9.48 | $9.05 | $7.64 | $11.18 | $12.31 | |
| EPS (Diluted) | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 | $12.41 | $6.27 | $10.21 | $8.89 | $8.50 | $7.17 | $10.48 | $11.66 | |
| Shares (Basic) | 102,800,000 | 104,000,000 | · | 103,600,000 | 105,100,000 | 106,700,000 | · | 108,100,000 | 108,100,000 | 107,800,000 | · | 106,300,000 | 107,000,000 | 107,100,000 | · | 106,900,000 | |
| Shares (Diluted) | 106,000,000 | 107,700,000 | · | 107,200,000 | 108,600,000 | 111,200,000 | · | 116,200,000 | 115,400,000 | 115,100,000 | · | 113,400,000 | 113,900,000 | 114,000,000 | · | 112,800,000 | |
| EBITDA | $1.29B | $766M | · | $1.03B | $1.08B | $719M | · | $1.18B | $1.07B | $866M | · | $1.11B | $1.02B | $1.05B | · | $1.22B |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B | $2.60B | $2.73B | $2.15B | $1.94B | $3.92B | $3.11B | $3.49B | |
| Short-term Investments | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B | $6.52B | $7.78B | $7.89B | $7.92B | · | $7.76B | $6.99B | $5.04B | · | $3.53B | |
| Receivables | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | $5.56B | $6.21B | $6.11B | $5.72B | $5.22B | · | $5.58B | $5.12B | $5.12B | · | $5.55B | |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B | $3.02B | $2.87B | $2.71B | · | $2.56B | $2.51B | $2.42B | · | $2.41B | |
| Prepaid Expense | $802M | $621M | $475M | $596M | $574M | $469M | $349M | $412M | $682M | $415M | · | $575M | $366M | $406M | · | $446M | |
| Current Assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B | $19.33B | $19.08B | $18.87B | · | $18.63B | $16.92B | $16.91B | · | $15.43B | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $3.70B | |
| Intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | $1.17B | $1.15B | $1.12B | $1.10B | $1.06B | · | $1.02B | $953M | $929M | · | $804M | |
| Other Non-current Assets | $2.31B | $2.13B | $1.82B | $1.67B | $1.54B | $1.39B | $1.14B | $1.04B | $994M | $470M | · | $410M | $393M | $350M | · | $320M | |
| Total Assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Accounts Payable | $1.16B | $1.03B | $939M | $904M | $724M | $706M | $790M | $497M | $562M | $671M | · | $537M | $547M | $600M | · | · | |
| Current Liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | $3.57B | $3.94B | $3.66B | $3.51B | $3.58B | · | $3.60B | $3.10B | $3.10B | · | $2.88B | |
| Capital Leases | · | · | $229M | · | · | · | $204M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.28B | $2.13B | $2.02B | $1.86B | $1.70B | $1.67B | $1.57B | $1.54B | $1.46B | $908M | · | $832M | $717M | $677M | · | $599M | |
| Total Liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B | $7.38B | · | $7.26B | $6.64B | $6.56B | · | $6.24B | |
| Total Debt | $1.99B | $1.99B | · | $1.99B | $1.99B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $14.70B | $14.40B | $13.99B | $13.79B | $13.49B | $13.19B | $12.86B | $12.70B | $12.32B | $11.94B | · | $11.25B | $10.89B | $10.60B | · | $9.52B | |
| Retained Earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | $32.38B | $31.67B | $30.76B | $29.41B | $27.98B | · | $26.10B | $25.09B | $24.12B | · | $22.11B | |
| Treasury Stock | $20.57B | $19.41B | $18.61B | $17.94B | $17.28B | $16.22B | $15.17B | $14.19B | $13.46B | $12.86B | · | $12.27B | $11.77B | $11.05B | · | $9.91B | |
| AOCI | $-36M | $12M | $78M | $69M | $52M | $29M | $-8M | $60M | $-70M | $-77M | · | $-177M | $-198M | $-182M | · | $-275M | |
| Stockholders' Equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B | $26.99B | $25.97B | $24.90B | $24.02B | $23.50B | $22.66B | $21.44B | |
| Liabilities + Equity | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Shares Outstanding | 138,000,000 | 137,900,000 | 137,600,000 | 136,200,000 | 136,200,000 | 136,100,000 | 136,000,000 | 135,300,000 | 134,800,000 | 134,200,000 | 133,100,000 | 132,100,000 | 131,600,000 | 131,400,000 | 130,400,000 | 129,000,000 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $124M | $123M | $145M | $137M | $135M | $127M | $126M | $122M | $121M | $114M | $113M | $105M | $103M | $100M | $100M | $93M | |
| Stock-based Comp | $243M | $257M | $249M | $237M | $252M | $256M | $304M | $225M | $223M | $230M | $240M | $204M | $202M | $239M | $232M | $166M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | $16M | |
| Other Non-cash | · | $-29M | · | · | · | $-146M | · | · | · | $446M | · | · | · | $212M | · | · | |
| Operating Cash Flow | $813M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354M | $1.51B | $1.09B | $1.11B | $1.02B | $1.37B | $1.72B | $629M | |
| CapEx | $240M | $231M | $249M | $201M | $219M | $229M | $200M | $242M | $180M | $134M | $251M | $176M | $113M | $178M | $152M | $142M | |
| Investing Cash Flow | $-93M | $-429M | $220M | $-403M | $-1.09B | $648M | $351M | $-574M | $-557M | $-1.69B | $-66M | $-496M | $-2.39B | $-236M | $-1.86B | $192M | |
| Stock Issued | $49M | $163M | $504M | $40M | $32M | $61M | $91M | $255M | $438M | $682M | $301M | $269M | $91M | $485M | $373M | $318M | |
| Stock Repurchased | $1.17B | $794M | $672M | $664M | $1.06B | $1.04B | $973M | $735M | $604M | $291M | $289M | $546M | $689M | $711M | $431M | $935M | |
| Net Stock Activity | · | $-631M | · | · | · | $-981M | · | · | · | $391M | · | · | · | $-226M | · | · | |
| Dividends Paid | $97M | $98M | $93M | $91M | $93M | $94M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.22B | $-802M | $-780M | $-718M | $-1.13B | $-1.09B | $-1.14B | $-634M | $-478M | $47M | $-446M | $-407M | $-614M | $-322M | $-248M | $-725M | |
| Net Change in Cash | $-505M | $-153M | $611M | $498M | $-1.08B | $604M | $477M | $84M | $-682M | $-128M | $578M | $210M | $-1.98B | $809M | $-385M | $96M | |
| Free Cash Flow | · | $848M | · | · | · | $816M | · | · | · | $1.38B | · | · | · | $1.19B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $1.36B | · | · | · | $1.17B | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 30.1% | 17.8% | · | 27.4% | 29.4% | 19.5% | · | 31.7% | 30.1% | 23.9% | · | 33.0% | 32.2% | 29.9% | · | 41.7% | |
| Net Margin | 30.2% | 20.2% | · | 38.9% | 37.9% | 26.7% | · | 36.0% | 40.4% | 23.0% | · | 30.0% | 30.7% | 25.9% | · | 44.8% | |
| Pretax Margin | 35.6% | 23.1% | · | 47.0% | 41.3% | 29.9% | · | 40.1% | 45.9% | 22.3% | · | 33.0% | 34.3% | 27.1% | · | 51.4% | |
| EBITDA Margin | 30.1% | 21.2% | · | 27.4% | 29.4% | 23.7% | · | 31.7% | 30.1% | 27.5% | · | 33.0% | 32.2% | 33.1% | · | 41.7% | |
| ROA | 3.2% | 1.8% | · | 3.8% | 3.8% | 2.2% | · | 3.9% | 4.3% | 2.2% | · | 3.4% | 3.4% | 2.9% | · | 5.1% | |
| ROE | 4.2% | 2.4% | · | 4.8% | 4.8% | 2.9% | · | 4.9% | 5.5% | 2.9% | · | 4.3% | 4.3% | 3.8% | · | 6.8% | |
| ROIC | 3.3% | 1.7% | · | 2.6% | 3.1% | 1.7% | · | 3.4% | 3.1% | 2.7% | · | 3.8% | 3.5% | 3.5% | · | 4.5% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.6 | · | 4.1 | 4.6 | 4.9 | · | 5.3 | 5.4 | 5.3 | · | 5.2 | 5.5 | 5.5 | · | 5.4 | |
| Quick Ratio | 2.6 | 2.8 | · | 3.2 | 3.6 | 3.9 | · | 4.3 | 4.4 | 4.4 | · | 4.3 | 4.5 | 4.5 | · | 4.4 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 46.7 | · | 62.4 | 53.8 | 52.6 | · | 80.0 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.5 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $229.79 | $227.87 | · | $227.30 | $219.82 | $215.93 | · | $216.75 | $209.24 | $201.13 | · | $188.53 | $182.51 | $178.81 | · | $166.19 | |
| Revenue / Share | $40.48 | $33.48 | · | $35.02 | $33.85 | $27.24 | · | $32.02 | $30.74 | $27.32 | · | $29.65 | $27.73 | $27.74 | · | $26.03 | |
| Cash Flow / Share | · | $10.02 | · | · | · | $9.40 | · | · | · | $13.14 | · | · | · | $12.00 | · | · | |
| Cash / Share | $17.80 | $21.48 | · | $18.40 | $14.65 | $22.71 | · | $14.87 | $14.25 | $19.39 | · | $16.29 | $14.72 | $29.80 | · | $27.06 | |
| Dividend / Share | $0.94 | $0.94 | $0.88 | $0.88 | $0.88 | $0.88 | · | · | · | · | · | · | · | · | · | · | |
| EPS (TTM) | $40.38 | $40.96 | · | $41.82 | $39.74 | $39.34 | · | $40.43 | $37.78 | $33.87 | · | $35.04 | $37.81 | $36.78 | · | $47.32 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $15.53B | $14.92B | · | $14.25B | $14.21B | $14.09B | · | $13.85B | $13.49B | $13.10B | · | $13.10B | $12.67B | $12.37B | · | $13.71B | |
| Net Income TTM | $4.33B | $4.42B | · | $4.58B | $4.46B | $4.50B | · | $4.65B | $4.32B | $3.86B | · | $3.99B | $4.30B | $4.18B | · | $5.37B | |
| Market Cap | $86.05B | $106.55B | · | $76.58B | $71.50B | $86.32B | · | $142.23B | $141.68B | $129.17B | · | $108.71B | $94.56B | $107.97B | · | $88.86B | |
| Enterprise Value | $80.04B | $99.78B | · | $70.12B | $66.02B | $79.95B | · | $134.42B | $133.85B | $120.63B | · | $100.78B | $87.61B | $100.99B | · | $83.82B | |
| P/E | 15.4 | 18.9 | · | 13.4 | 13.2 | 16.1 | · | 26.0 | 27.8 | 28.4 | · | 23.5 | 19.0 | 22.3 | · | 14.6 | |
| P/S | 5.5 | 7.1 | · | 5.4 | 5.0 | 6.1 | · | 10.3 | 10.5 | 9.9 | · | 8.3 | 7.5 | 8.7 | · | 6.5 | |
| P/B | 2.7 | 3.4 | · | 2.5 | 2.4 | 2.9 | · | 4.9 | 5.0 | 4.8 | · | 4.4 | 3.9 | 4.6 | · | 4.1 | |
| P / Tangible Book | 2.8 | 3.5 | · | 2.6 | 2.5 | 3.1 | · | 5.0 | 5.2 | 5.0 | · | 4.6 | 4.1 | 4.8 | · | 4.3 | |
| P / Cash Flow | · | 98.8 | · | · | · | 82.6 | · | · | · | 85.4 | · | · | · | 78.9 | · | · | |
| EV / Revenue | 5.2 | 6.7 | · | 4.9 | 4.6 | 5.7 | · | 9.7 | 9.9 | 9.2 | · | 7.7 | 6.9 | 8.2 | · | 6.1 | |
| Dividend Yield | 0.44% | 0.35% | · | 0.36% | 0.26% | 0.11% | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 6.5% | 5.3% | · | 7.4% | 7.6% | 6.2% | · | 3.9% | 3.6% | 3.5% | · | 4.3% | 5.3% | 4.5% | · | 6.9% | |
| Payout Ratio | · | 13.5% | · | · | · | 11.6% | · | · | · | · | · | · | · | · | · | · | |
| Annual Payout | $378M | $374M | · | $278M | $186M | $94M | · | · | · | · | · | · | · | · | · | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Operating Margin % | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Current Ratio | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B |
Institutional owners (13F) 1,465 filers · $65.3B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 116 (-49 vs prior Q) | 163 (+65 vs prior Q) | 494 (-80 vs prior Q) | 549 (+72 vs prior Q) | +2.3M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $7,004,838,346 | 9,075,153 | 10.73% | Shares |
| BlackRock, Inc. | $5,682,635,642 | 9,113,506 | 8.70% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $4,133,919,926 | 6,629,759 | 6.33% | Shares |
| Dodge & Cox | $3,037,348,765 | 4,871,137 | 4.65% | Shares |
| STATE STREET CORP | $3,014,621,356 | 4,834,688 | 4.62% | Shares |
| Invesco Ltd. | $2,457,161,872 | 3,940,665 | 3.76% | Shares |
| JPMORGAN CHASE & CO | $2,384,577,378 | 3,774,199 | 3.65% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1,979,934,668 | 3,175,313 | 3.03% | Shares |
| FRANKLIN RESOURCES INC | $1,728,352,744 | 2,771,839 | 2.65% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,632,283,060 | 2,625,810 | 2.50% | Shares |
| Nuveen, LLC | $1,259,533,994 | 2,019,974 | 1.93% | Shares |
| LOOMIS SAYLES & CO L P | $1,159,268,030 | 1,859,172 | 1.78% | Shares |
| PeakShares LLC | $975,217,000 | 1,564 | 1.49% | Shares |
| MORGAN STANLEY | $871,531,343 | 1,397,712 | 1.33% | Shares |
| BANK OF AMERICA CORP /DE/ | $805,023,383 | 1,291,053 | 1.23% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $791,950,049 | 1,270,087 | 1.21% | Shares |
| NORGES BANK | $731,292,700 | 1,172,808 | 1.12% | Shares |
| GOLDMAN SACHS GROUP INC | $725,295,767 | 1,163,191 | 1.11% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $702,155,889 | 1,126,080 | 1.08% | Shares |
| Amundi | $631,982,733 | 1,013,540 | 0.97% | Shares |
| NORTHERN TRUST CORP | $571,453,833 | 916,467 | 0.88% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $559,098,531 | 723,621 | 0.86% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $527,705,643 | 846,306 | 0.81% | Shares |
| FMR LLC | $518,763,486 | 831,964 | 0.79% | Shares |
| Capital World Investors | $508,138,359 | 814,925 | 0.78% | Shares |
| Legal & General Group Plc | $473,872,322 | 759,971 | 0.73% | Shares |
| Bank of New York Mellon Corp | $472,950,278 | 758,492 | 0.72% | Shares |
| TWO SIGMA ADVISERS, LP | $466,626,290 | 604,540 | 0.71% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $432,674,406 | 693,900 | 0.66% | Put option |
| TWO SIGMA INVESTMENTS, LP | $409,119,559 | 656,124 | 0.63% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $351,496,357 | 563,711 | 0.54% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $349,040,316 | 559,687 | 0.53% | Shares |
| FIRST TRUST ADVISORS LP | $341,158,711 | 547,132 | 0.52% | Shares |
| DEUTSCHE BANK AG\ | $323,248,747 | 518,409 | 0.50% | Shares |
| Robeco Institutional Asset Management B.V. | $287,203,770 | 460,602 | 0.44% | Shares |
| Man Group plc | $272,459,544 | 436,956 | 0.42% | Shares |
| NEUBERGER BERMAN GROUP LLC | $263,118,974 | 421,976 | 0.40% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $249,320,598 | 399,847 | 0.38% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $245,478,345 | 393,685 | 0.38% | Shares |
| HSBC HOLDINGS PLC | $238,531,538 | 382,028 | 0.37% | Shares |
| Allianz Asset Management GmbH | $237,330,548 | 380,618 | 0.36% | Shares |
| National Pension Service | $236,829,845 | 379,815 | 0.36% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $236,259,306 | 378,900 | 0.36% | Call option |
| NORDEA INVESTMENT MANAGEMENT AB | $227,370,654 | 363,479 | 0.35% | Shares |
| ALLIANCEBERNSTEIN L.P. | $225,872,032 | 292,338 | 0.35% | Shares |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $220,714,454 | 353,970 | 0.34% | Shares |
| CITIGROUP INC | $216,142,066 | 346,637 | 0.33% | Shares |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $206,740,923 | 331,560 | 0.32% | Shares |
| JANE STREET GROUP, LLC | $198,659,844 | 318,600 | 0.30% | Call option |
| UBS Group AG | $185,960,829 | 298,234 | 0.28% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC., SYMPHONY ACQUISITION SUB, INC. ×2 filings | Sept. 27, 2023 | · | Initial filing | · | SEC |
| Sanofi ×17 filings | June 17, 2020 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 39 insiders · 10 officers · 12 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | Dec. 31, 2025 M | 214,523 | 0 | 0 | $0 |
| Christopher R. Fenimore | EVP Finance CFO | Aug. 18, 2026 M | 19,984 | 0 | 0 | $0 |
| Robert E Landry | EVP Finance CFO | Feb. 2, 2024 M | 23,693 | 0 | 0 | $0 |
| Marion Mccourt | EVP Commercial | Sept. 3, 2026 S | 12,003 | 0 | 2 | $-2,002,458 |
| Joseph J Larosa | EVP General Counsel and Secret | Aug. 19, 2026 M | 36,373 | 0 | 0 | $0 |
| Jason Pitofsky | SVP Controller | Feb. 9, 2026 M | 4,272 | 0 | 12 | $-1,865,824 |
| Andrew J Murphy | EVP Research | Dec. 9, 2025 F | 47,833 | 0 | 0 | $0 |
| Van Plew Daniel P | EVP & General Mgr, Industrial | Dec. 9, 2025 F | 21,673 | 0 | 0 | $0 |
| Neil Stahl | EVP Research and Development | Dec. 16, 2024 F | 48,829 | 0 | 0 | $0 |
| Michael S Aberman | SVP Strategy Investor Relation | June 21, 2017 M | 4,693 | 0 | 0 | $0 |
| Kathryn Guarini | Director | Sept. 2, 2026 M | 603 | 0 | 2 | $-660,000 |
| Huda Y Zoghbi | Director | Aug. 10, 2026 M | 1,703 | 0 | 12 | $-1,919,812 |
| Arthur F Ryan | Director | July 2, 2026 S | 17,303 | 0 | 48 | $-434,683 |
| Bonnie L Bassler | Director | Jan. 7, 2026 M | 1,703 | 0 | 2 | $-1,770,000 |
| David P Schenkein | Director | Jan. 2, 2026 A | 603 | 0 | 0 | $0 |
| Craig B. Thompson | Director | Jan. 2, 2026 A | 775 | 0 | 0 | $0 |
| Anthony N Coles | Director | Jan. 2, 2026 A | 1,714 | 0 | 0 | $0 |
| Christine A Poon | Director | Jan. 2, 2026 A | 5,219 | 0 | 6 | $-4,252,745 |
| Michael S Brown | Director | Jan. 2, 2026 A | 1,703 | 0 | 0 | $0 |
| VAGELOS P ROY | Director | April 3, 2023 G | 125,493 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | Director | Jan. 3, 2023 A | 2,434 | 0 | 0 | $0 |
| Sanofi | 10% owner | June 9, 2020 S | 279,766 | 0 | 0 | $0 |
| Pharma Ag Novartis | 10% owner | Nov. 8, 2005 S | · | 0 | 0 | $0 |
| Joseph L Goldstein | · | Jan. 2, 2026 A | 6,703 | 0 | 0 | $0 |
| George L Sing | · | Jan. 2, 2026 A | 31,007 | 0 | 0 | $0 |
| George Yancopoulos | · | Dec. 31, 2025 M | 310,460 | 0 | 0 | $0 |
| Charles A Baker | · | Jan. 2, 2018 A | 9,000 | 0 | 0 | $0 |
| Robert J Terifay | · | Dec. 12, 2017 A | 25,214 | 0 | 0 | $0 |
| Peter Powchik | · | Dec. 16, 2016 A | 2,459 | 0 | 0 | $0 |
| Douglas S Mccorkle | · | Dec. 29, 2015 M | 6,866 | 0 | 0 | $0 |
| Alfred G Gilman | · | Aug. 6, 2015 M | 8,912 | 0 | 0 | $0 |
| Robert Alexander Ingram | · | May 22, 2015 M | 1,500 | 0 | 0 | $0 |
| Murray A Goldberg | · | Dec. 16, 2014 A | 64,436 | 0 | 0 | $0 |
| Eric M Shooter | · | Feb. 12, 2014 M | 0 | 0 | 0 | $0 |
| William Roberts | · | Sept. 18, 2013 M | 13,447 | 0 | 0 | $0 |
| Stuart Kolinski | · | June 3, 2010 M | 16,329 | 0 | 0 | $0 |
| Peter Dworkin | · | Dec. 18, 2009 A | · | 0 | 0 | $0 |
| Randall Rupp | · | April 13, 2007 M | 3,983 | 0 | 0 | $0 |
| Hans Peter Guler | · | Oct. 8, 2004 M | 10,530 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 164 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| TBXU · Direxion Shares ETF Trust | 9.09% | 306 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 5.92% | 771,203 SH | Sept. 11, 2026 | Daily |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 4.97% | 7,153 SH | Oct. 2, 2026 | Daily |
| PBE · Invesco Exchange-Traded Fund Trust | 4.57% | 25,808 SH | Oct. 2, 2026 | Daily |
| IDNA · iShares Trust | 3.86% | 12,451 SH | Sept. 11, 2026 | Daily |
| PJP · Invesco Exchange-Traded Fund Trust | 2.87% | 21,443 SH | Oct. 2, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 2.77% | 38,060 NS | July 31, 2026 | N-PORT |
| SMRI · EA Series Trust | 2.16% | 18,239 NS | July 31, 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.97% | 1,789 NS | July 31, 2026 | N-PORT |
| QQQG · Pacer Funds Trust | 1.77% | 474 NS | July 31, 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.72% | 2,218 NS | July 31, 2026 | N-PORT |
| SDG · iShares Trust | 1.61% | 3,380 SH | Sept. 11, 2026 | Daily |
| TECB · iShares Trust | 1.60% | 9,957 SH | Sept. 11, 2026 | Daily |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 1.60% | 190 NS | July 31, 2026 | N-PORT |
| QNXT · iShares Trust | 1.57% | 539 SH | Sept. 11, 2026 | Daily |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.50% | 17,808 SH | Oct. 2, 2026 | Daily |
| RILA · Spinnaker ETF Series | 1.50% | 828 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1.36% | 333,418 NS | July 31, 2026 | N-PORT |
| NUGO · Nushares ETF Trust | 1.35% | 43,305 NS | July 31, 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1.34% | 33,267 SH | Oct. 2, 2026 | Daily |
| IYH · iShares Trust | 1.29% | 59,163 SH | Sept. 11, 2026 | Daily |
| QQQE · Direxion Shares ETF Trust | 1.26% | 22,110 NS | July 31, 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1.24% | 4,396 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1.15% | 49,425 NS | July 31, 2026 | N-PORT |
| IMCV · iShares Trust | 1.12% | 16,393 SH | Sept. 11, 2026 | Daily |
| RDVI · First Trust Exchange-Traded Fund IV | 1.04% | 49,112 NS | July 31, 2026 | N-PORT |
| IXJ · iShares Trust | 1.00% | 52,534 SH | Sept. 11, 2026 | Daily |
| CVAR · ETF Opportunities Trust | 0.99% | 556 NS | July 31, 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0.95% | 374 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.95% | 312,338 SH | Aug. 19, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.87% | 1,966 NS | July 31, 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.87% | 2,762 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.87% | 5,608 NS | July 31, 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0.84% | 15,425 NS | July 31, 2026 | N-PORT |
| QIDX · Spinnaker ETF Series | 0.81% | 413 NS | July 31, 2026 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0.74% | 2,831 NS | July 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.73% | 8,277 SH | Aug. 19, 2026 | Daily |
| PEXL · Pacer Funds Trust | 0.64% | 428 NS | July 31, 2026 | N-PORT |
| JOYT · J.P. Morgan Exchange-Traded Fund Tr… | 0.62% | 798 NS | July 31, 2026 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.61% | 5,194 NS | July 31, 2026 | N-PORT |
| COWG · Pacer Funds Trust | 0.60% | 17,254 NS | July 31, 2026 | N-PORT |
| LCOW · Pacer Funds Trust | 0.57% | 193 NS | July 31, 2026 | N-PORT |
| IMCB · iShares Trust | 0.56% | 11,793 SH | Sept. 11, 2026 | Daily |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.55% | 11,300 NS | July 31, 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0.55% | 330,891 SH | Aug. 19, 2026 | Daily |
| FVAL · FIDELITY COVINGTON TRUST | 0.54% | 9,350 NS | July 31, 2026 | N-PORT |
| VLLU · Harbor ETF Trust | 0.53% | 32 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.50% | 6,827 SH | Aug. 19, 2026 | Daily |
| HELO · J.P. Morgan Exchange-Traded Fund Tr… | 0.50% | 30,053 NS | July 31, 2026 | N-PORT |
| XT · iShares Trust | 0.45% | 21,982 SH | Sept. 11, 2026 | Daily |
| XOEF · iShares Trust | 0.45% | 126 SH | Sept. 11, 2026 | Daily |
| LRND · New York Life Investments ETF Trust | 0.45% | 2,326 NS | July 31, 2026 | N-PORT |
| FAB · First Trust Exchange-Traded AlphaDE… | 0.42% | 931 NS | July 31, 2026 | N-PORT |
| QYLG · Global X Funds | 0.36% | 749 NS | July 31, 2026 | N-PORT |
| QYLD · Global X Funds | 0.36% | 38,252 NS | July 31, 2026 | N-PORT |
| QTR · Global X Funds | 0.36% | 36 NS | July 31, 2026 | N-PORT |
| PTNQ · Pacer Funds Trust | 0.36% | 5,637 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.36% | 22,905 SH | Oct. 2, 2026 | Daily |
| QQWZ · Pacer Funds Trust | 0.35% | 235 NS | July 31, 2026 | N-PORT |
| QRMI · Global X Funds | 0.35% | 65 NS | July 31, 2026 | N-PORT |
| QCLR · Global X Funds | 0.35% | 15 NS | July 31, 2026 | N-PORT |
| LGDX · Tidal Trust III | 0.34% | 635 NS | July 31, 2026 | N-PORT |
| FYEE · Fidelity Greenwood Street Trust | 0.34% | 963 NS | July 31, 2026 | N-PORT |
| QSIX · Pacer Funds Trust | 0.33% | 80 NS | July 31, 2026 | N-PORT |
| USXF · iShares Trust | 0.33% | 6,121 SH | Sept. 11, 2026 | Daily |
| JQUA · J.P. Morgan Exchange-Traded Fund Tr… | 0.31% | 33,693 NS | July 31, 2026 | N-PORT |
| QQQM · Invesco Exchange-Traded Fund Trust … | 0.31% | 465,347 SH | Oct. 2, 2026 | Daily |
| VO · VANGUARD INDEX FUNDS | 0.31% | 1,116,350 SH | Aug. 19, 2026 | Daily |
| QQQ · Invesco QQQ Trust, Series 1 | 0.31% | 2,118,378 SH | Oct. 2, 2026 | Daily |
| IWX · iShares Trust | 0.30% | 14,575 SH | Sept. 11, 2026 | Daily |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.29% | 9,331,000 | Oct. 2, 2026 | Daily |
| FBUF · Fidelity Greenwood Street Trust | 0.29% | 90 NS | July 31, 2026 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.27% | 54,168 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.27% | 166,174 SH | Sept. 11, 2026 | Daily |
| ROUS · Lattice Strategies Trust | 0.26% | 2,402 NS | July 31, 2026 | N-PORT |
| IUSV · iShares Trust | 0.25% | 87,534 SH | Sept. 11, 2026 | Daily |
| PWS · Pacer Funds Trust | 0.24% | 77 NS | July 31, 2026 | N-PORT |
| VTV · VANGUARD INDEX FUNDS | 0.24% | 980,743 SH | Aug. 19, 2026 | Daily |
| ILCV · iShares Trust | 0.23% | 3,924 SH | Sept. 11, 2026 | Daily |
| SIZE · iShares Trust | 0.23% | 1,250 SH | Sept. 11, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.22% | 19,823 NS | July 31, 2026 | N-PORT |
| EVUS · iShares Trust | 0.22% | 1,047 SH | Sept. 11, 2026 | Daily |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.22% | 2,852 SH | Oct. 2, 2026 | Daily |
| IWD · iShares Trust | 0.22% | 224,598 SH | Sept. 11, 2026 | Daily |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.22% | 1,293 NS | July 31, 2026 | N-PORT |
| REVS · Columbia ETF Trust I | 0.21% | 937 NS | July 31, 2026 | N-PORT |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.21% | 23,015 SH | Aug. 19, 2026 | Daily |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.20% | 298,000 | Oct. 2, 2026 | Daily |
| WRND · New York Life Investments ETF Trust | 0.20% | 27 NS | July 31, 2026 | N-PORT |
| EUSA · iShares, Inc. | 0.19% | 4,642 SH | Sept. 11, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.19% | 25,214 SH | Oct. 2, 2026 | Daily |
| DYNF · BlackRock ETF Trust | 0.19% | 97,867 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.19% | 241,736 SH | Oct. 2, 2026 | Daily |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.18% | 61,026 SH | Aug. 19, 2026 | Daily |
| HAPI · Harbor ETF Trust | 0.18% | 1,128 NS | July 31, 2026 | N-PORT |
| ACVF · ETF Opportunities Trust | 0.17% | 345 NS | July 31, 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.17% | 1,881 NS | July 31, 2026 | N-PORT |
| ACWV · iShares, Inc. | 0.17% | 7,224 SH | Sept. 11, 2026 | Daily |
| MGV · VANGUARD WORLD FUND | 0.15% | 32,377 SH | Aug. 19, 2026 | Daily |
| TOPC · iShares Trust | 0.15% | 61 SH | Sept. 11, 2026 | Daily |
| IWL · iShares Trust | 0.14% | 3,916 SH | Sept. 11, 2026 | Daily |
| XVV · iShares Trust | 0.14% | 1,147 SH | Sept. 11, 2026 | Daily |
| VFMO · VANGUARD WELLINGTON FUND | 0.13% | 4,312 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.13% | 440 NS | July 31, 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.13% | 2,861 SH | Oct. 2, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.13% | 907 NS | July 31, 2026 | N-PORT |
| XYLD · Global X Funds | 0.12% | 5,308 NS | July 31, 2026 | N-PORT |
| XRMI · Global X Funds | 0.12% | 81 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.12% | 20,024 NS | July 31, 2026 | N-PORT |
| ILCB · iShares Trust | 0.12% | 1,968 SH | Sept. 11, 2026 | Daily |
| IVV · iShares Trust | 0.12% | 1,259,511 SH | Sept. 11, 2026 | Daily |
| SUSA · iShares Trust | 0.12% | 6,108 SH | Sept. 11, 2026 | Daily |
| XYLG · Global X Funds | 0.12% | 101 NS | July 31, 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0.12% | 5,110 NS | July 31, 2026 | N-PORT |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.12% | 13,862 NS | July 31, 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0.12% | 8,507 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.12% | 1,704 NS | July 31, 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0.12% | 9 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.12% | 3,461 NS | July 31, 2026 | N-PORT |
| USCL · iShares Trust | 0.12% | 4,111 SH | Sept. 11, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.12% | 8,835 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.12% | 5,040 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.11% | 70,097 SH | Sept. 11, 2026 | Daily |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.11% | 17,850 SH | Oct. 2, 2026 | Daily |
| IYY · iShares Trust | 0.11% | 4,310 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.11% | 30,416 NS | July 31, 2026 | N-PORT |
| XTR · Global X Funds | 0.11% | 7 NS | July 31, 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0.11% | 585 SH | Oct. 2, 2026 | Daily |
| IWV · iShares Trust | 0.11% | 28,027 SH | Sept. 11, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.11% | 22,848 SH | Aug. 19, 2026 | Daily |
| SPUU · Direxion Shares ETF Trust | 0.11% | 377 NS | July 31, 2026 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.11% | 466 NS | July 31, 2026 | N-PORT |
| ITOT · iShares Trust | 0.11% | 130,118 SH | Sept. 11, 2026 | Daily |
| XCLR · Global X Funds | 0.11% | 5 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.11% | 2,376 NS | July 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.10% | 2,594,549 SH | Aug. 19, 2026 | Daily |
| VV · VANGUARD INDEX FUNDS | 0.10% | 120,313 SH | Aug. 19, 2026 | Daily |
| TILT · FlexShares Trust | 0.10% | 2,844 NS | July 31, 2026 | N-PORT |
| ESGU · iShares Trust | 0.10% | 21,548 SH | Sept. 11, 2026 | Daily |
| TOK · iShares Trust | 0.10% | 284 SH | Sept. 11, 2026 | Daily |
| HCMT · Direxion Shares ETF Trust | 0.09% | 697 NS | July 31, 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.09% | 77 SH | Oct. 2, 2026 | Daily |
| URTH · iShares, Inc. | 0.09% | 9,338 SH | Sept. 11, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.09% | 3,271,463 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.09% | 16,748 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.09% | 8,511 SH | Aug. 19, 2026 | Daily |
| SPXL · Direxion Shares ETF Trust | 0.09% | 7,811 NS | July 31, 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.09% | 953 SH | Oct. 2, 2026 | Daily |
| ESMV · iShares Trust | 0.08% | 8 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.08% | 33,015 SH | Sept. 11, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.08% | 49,604 NS | July 31, 2026 | N-PORT |
| CRBN · iShares Trust | 0.07% | 1,102 SH | Sept. 11, 2026 | Daily |
| USMV · iShares Trust | 0.07% | 22,355 SH | Sept. 11, 2026 | Daily |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.07% | 9,583 SH | Oct. 2, 2026 | Daily |
| MGC · VANGUARD WORLD FUND | 0.06% | 10,338 SH | Aug. 19, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.05% | 85,176 SH | Aug. 19, 2026 | Daily |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| VCEB · VANGUARD WORLD FUND | · | · | July 30, 2026 | Daily |
REGN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
26 analysts · 2026-09-30Mean target $850.88 +15.7%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | · |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | · |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | · |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | · |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | · |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | · |
| RVMD | · | · | · | · | · | · |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | · |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.